AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
The call open interest at $240 (
) and $250 () is massive—over 20,000 contracts combined. That’s not just noise; it’s a bet that will reclaim its 52-week high by Friday. But here’s the twist: the stock is currently 13% below $240. For those calls to pay off, ABBV needs a sharp reversal.Meanwhile, the $185 put (
) has 3,403 open contracts, hinting at a floor if the sell-off accelerates. The put/call ratio of 0.77 (calls > puts) leans bullish, but don’t ignore the block trade at ABBV20251017C230—6,138 contracts traded at $230. That’s a whale-sized bet on a rebound, not a crash.Earnings Beat and Pipeline Hype vs. Valuation ConcernsAbbVie’s Q3 beat and dividend raise ($1.73/share) are solid, but BofA’s $233 target cut reflects reality: the stock trades at a 172 P/E, way above its 5-year average. Analysts love the pipeline (Rinvoq expansions, tavapadon), but those won’t boost the stock overnight. Institutional buyers (Shorepoint, GAMMA) are piling in, but retail traders should ask: Is this a "buy the rumor" play or a "sell the news" trap?
Actionable Trades for ABBV: Calls, Puts, and Precision EntriesABBV is caught between a rock (high valuation) and a hard place (pipeline optimism). The options data leans bullish, but don’t ignore the puts at $185–$200—they’re a warning sign. If the stock holds above $220, this could be a short-term buying opportunity. But if it cracks $217.50, brace for a test of the 200D MA at $205.22. Either way, the next 72 hours will clarify whether this is a rebound or a breakdown.

Focus on daily option trades

Dec.16 2025

Dec.16 2025

Dec.16 2025

Dec.16 2025

Dec.16 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet